Delving into the Latest Updates on Autologous Adipose Derived Mesenchymal Cells(Regeneris Medical) with Synapse

Overview

Basic Info

Drug Type

Mesenchymal stem cell therapy

Synonyms

Autologous Adipose MSC's(Regeneris Medical)

Target-

Action-

Mechanism-

Therapeutic Areas

Infectious DiseasesRespiratory Diseases

Active Indication

COVID-19

Inactive Indication-

Originator Organization

Regeneris Medical

Active Organization

Regeneris Medical

Inactive Organization-

License Organization-

Drug Highest PhasePhase 1

First Approval Date-

Regulation-

The aim of this study is to evaluate the safety and efficacy of autologous adipose-derived mesenchymal cells for treating confirmed or suspected patients with SARS-CoV-2 and compromised respiratory function requiring hospitalization.
The hypothesis of the Study is autologous adipose-derived mesenchymal cells given IV to eligible patients will improve clinical outcomes of COVID 19 positive patients with severe pneumonia or ARDS by reducing or avoiding cytokine storm.

Start Date01 Apr 2020

Sponsor / Collaborator

Regeneris Medical

100 Clinical Results associated with Autologous Adipose Derived Mesenchymal Cells(Regeneris Medical)

Login to view more data

100 Translational Medicine associated with Autologous Adipose Derived Mesenchymal Cells(Regeneris Medical)

Login to view more data

100 Patents (Medical) associated with Autologous Adipose Derived Mesenchymal Cells(Regeneris Medical)

Login to view more data

100 Deals associated with Autologous Adipose Derived Mesenchymal Cells(Regeneris Medical)

Login to view more data